‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant

• DOI: 10.1016/j.aohep.2021.100337
• Publication Date: 2021-03-07T09:50:34Z
• Authors: Fabrizio Fabrizi; Cristina Alonso; Ana Palazzo; Margarita Anders; Maria Virginia Re...; Hugo Cheinquer; Maria Grazia Vide...; Sebastian Figueroa; Manuel Mendizabal; Marcelo Silva; Ezequiel Ridruejo
• Keywords: Ombitasvir; Sofosbuvir; Dasabuvir; Paritaprevir; Daclatasvir; Ledipasvir; Ritonavir; Hepatitis C; Simeprevir

The introduction of direct-acting antiviral (DAA) agents promises to change dramatically the management hepatitis C in kidney transplant recipients, a patient group where treatment is historically challenging. purpose current study was assess (in 'real-life' setting) safety and efficacy all-oral, interferon-free, recipients with HCV. We performed single-arm, multi-center cohort (n = 95) who underwent therapy DAAs. primary end-point sustained virologic response (SVR) (serum HCV RNA < 15 IU/mL, 12 weeks after ended; SVR12). recorded data on on-treatment adverse events (AEs), serious AEs, laboratory abnormalities. Various regimens were adopted at discretion treating physician: elbasvir/grazoprevir 11), paritaprevir/ritonavir/ombitasvir/dasabuvir (PrOD) ± ribavirin 23), sofosbuvir-based 61). SVR12 rate 93.7% (89/95) (95% CI, 88%; 98%), according intention-to-treat analysis; three patients without viral 3) found. Ribavirin administered 8 (8.4%) allograft recipients. frequency drop-outs 4.2% (4/95) 0.2%; 8.2%); these related arthralgia/myalgia 2), fatigue 1), lowered estimated glomerular filtration (eGFR) 1). There no differences regard serum creatinine eGFR before during follow-up whole cohort. interrupted due raised sofosbuvir/daclatasvir regimen; one four obtained SVR. All-oral, interferon-free DAAs for chronic transplantation effective well-tolerated 'real–life' clinical setting. Identical results have been observed intact kidneys or advanced disease. Careful evaluation function over received recommended. Clinical trials aimed whether translates into improved patient/graft survival are under way.